New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:45 EDTINSYInsys Therapeutics price target raised to $99 from $50 at JMP Securities
JMP Securities increased its price target on Insys after the company reported higher than expected earnings. The firm expects the company to benefit from continued growth in its Subsys drug and further advances in its pipeline. JMP Securities reiterates an Outperform rating on the stock.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:12 EDTINSYInsys Therapeutics price target raised to $57 from $53 at RBC Capital
Subscribe for More Information
December 9, 2014
07:12 EDTINSYInsys Therapeutics receives FDA orphan drug designation for LEP-ETU
Insys Therapeutics announced that the FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.
December 8, 2014
10:35 EDTINSYInsys Therapeutics management to meet with Piper Jaffray
Subscribe for More Information
10:00 EDTINSYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:18 EDTINSYInsys Therapeutics initiated with a Buy at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use